Fotona D.O.O. secured 510(k) clearance for its Dynamis Pro Family of lasers, positioning it for market entry as a substantially equivalent device in plastic surgery.
Fotona D.O.O. has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Dynamis Pro Family of laser systems. The clearance, identified as K252723, was issued on September 19, 2026, affirming the device's substantial equivalence to previously cleared systems.
The Dynamis Pro Family falls under product code GEX, indicating a laser surgical instrument for use in general and plastic surgery. The FDA classified the device as Class II, a designation for moderate-risk devices that typically require 510(k) premarket notification.
The traditional 510(k) pathway for clearance relies on demonstrating that a new device is as safe and effective as a legally marketed predicate device. Fotona submitted a summary statement to the FDA, outlining the device's characteristics and its equivalence.
Device Specification and Market Position
While specific technical details of the Dynamis Pro Family were not disclosed in the FDA's public record, the GEX product code often applies to pulsed or continuous wave lasers used for incision, excision, vaporization, ablation, and coagulation of soft tissue. These applications are common in aesthetic and reconstructive plastic surgery procedures.
Fotona, a Slovenian-based company, has a portfolio of laser systems. The Dynamis Pro Family's clearance suggests an expansion or update to their existing offerings for the U.S. market. The company has not yet released details regarding commercial availability, pricing, or the precise indications for which the Dynamis Pro Family will be marketed.
Regulatory Context for Laser Systems
Medical lasers are subject to FDA regulation due to their potential for harm if improperly designed or used. The Class II designation requires manufacturers to adhere to general controls and special controls, if any, to ensure safety and effectiveness. This includes performance standards, patient labeling, and sometimes post-market surveillance.
The substantial equivalence determination means the FDA did not find the Dynamis Pro Family to raise any new questions of safety or effectiveness compared to predicate devices. This clearance permits Fotona to market the device in the United States, competing within the established market for surgical and aesthetic lasers.
